Evotaz Approval History
Evotaz (atazanavir and cobicistat) is a once-daily fixed-dose combination of a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.
Development History and FDA Approval Process for Evotaz
|Jan 29, 2015||FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults|
|Apr 14, 2014||Bristol-Myers Squibb Submits NDA to FDA for Fixed-Dose Combination of Atazanavir Sulfate with Cobicistat|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.